Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — Eyegate Pharmaceuticals — Merger or Acquisition (March 2016)
16 slides from Kiora Pharmaceuticals's merger presentation, Mar 7, 2016
Slide 1: Acquisition of Jade Therapeutics
EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Acquisition of Jade Therapeutics
Slide 2: Forward Looking Statements
1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company’s lead product EGP - 437, for the timing and outcome of the Company’s
Slide 3: Acquisition Overview: Consideration
2 Acquisition Overview ▪ Consideration ▪ Will repay Jade liabilities of up to $ 300,000 ▪ Will issue 765,728 shares of EyeGate common stock (10% of outstanding common stock) • 90 % were issued at closing and 10% held back for 18 months to satisfy post - closing adjustments or indemnification obligat
Slide 4: Acquisition Overview: Corporate
3 Acquisition Overview ▪ Corporate ▪ EYEG will have R&D facility in Salt Lake City, Utah, home of Jade ▪ Strong research team ▪ Senior management has joined EYEG Barbara Wirostko M.D. Chief Medical Officer • A co - founder of Jade Therapeutics and a board certified ophthalmologist • Maintains academ
Slide 5: The Jade Platform
4 The Jade Platform ▪ Jade’s proprietary cross - linked thiolated hyaluronic acid (CMHA - S) platform • It begins with hyaluronic acid ( HA) – a polymer of disaccharides • Carboxymethyl groups are added to produce CMHA • The carboxymethyl groups are then thiolated using a proprietary method producin
Slide 6: Why Hyaluronic Acid (HA)
5 Why Hyaluronic Acid (HA) ▪ It occurs naturally in the human body and is central to regulating cell growth and renewal • Has intrinsic wound - healing capabilities, as well as anti - inflammatory and anti - adhesive properties ▪ HA is found extensively in connective, epithelial, and neural cells •
Slide 7: Why Modify HA
CONFIDENTIAL CONFIDENTIAL 6 Why Modify HA ▪ Native HA has a relatively short half - life • The average person has roughly 15 grams of HA in the body, one - third of which is turned over (degraded and synthesized) every day. It is degraded by a family of enzymes called hyaluronidases. ▪ Crosslinking
Slide 8: Real World Animal Experience
CONFIDENTIAL CONFIDENTIAL 7 Real World Animal Experience ▪ CMHA - S has demonstrated global safety and efficacy in small animals in real world setting ▪ Masked studies completed demonstrating efficacy • JDE - 001 (0.4 % concentration) – Masked, randomized 20 - dog DED study: superior efficacy vs. no
Slide 9: The Jade Pipeline
CONFIDENTIAL CONFIDENTIAL 8 The Jade Pipeline Product # Product Type of Product Indication Formulation Preclinical Development IND/IDE JDE - 003 Device Thiolated - HA Topical Drop (0.75%) Corneal Repair JDE - 001 Drug Thiolated - HA Topical Drop (0.4%) Dry Eye Disease (DED) JDE - 002* Device Thiolat
Slide 10: Lead Candidate: Large Unmet Medical Need
CONFIDENTIAL CONFIDENTIAL 9 Lead Candidate: Large Unmet Medical Need JDE - 003 (0.75% Concentration) ▪ Addressing Large Unmet Medical Need in Corneal Repair • Currently no US - approved eye drop to promote corneal wound repair • Corneal specialists desire a product that improves/accelerates healing
Slide 11: Lead Candidate: Competition
CONFIDENTIAL CONFIDENTIAL 10 Lead Candidate: Competition JDE - 003 (0.75% Concentration) ▪ AmbioDisk TM from IOP Ophthalmics ) is an amniotic membrane (AM ) device - a sutureless , overlay AM disk for the office - based or surgical treatment of the ocular surface. ($800/ treatment) ▪ Prokera ® (from
Slide 12: Lead Candidate: Market Size
CONFIDENTIAL CONFIDENTIAL 11 Lead Candidate: Market Size JDE - 003 (0.75% Concentration)
Slide 13: Ocular Surface Shield
CONFIDENTIAL CONFIDENTIAL 12 Ocular Surface Shield ▪ Medical Need: A sterile, field - stable product that is easily applied to immediately protect and promote healing of the ocular surface (Collagen Bandage Contact Lens) ▪ Design : A thin film, contoured to the shape of the globe/ocular surface, tha
Slide 14: Ocular Surface Shield DoD Phase II Status
CONFIDENTIAL CONFIDENTIAL 13 Ocular Surface Shield DoD Phase II Status ▪ 4 months completed ▪ Computational modeling (Dr. Brittany Coats1) • Mechanical properties of films, properties of ocular surface, shape and size of eye, blink, and eye movement used to inform shape and size of film • Model used
Slide 15: Topical Sustained-Release Delivery Antibiotics: Bacterial Keratitis/Conjunctivitis
CONFIDENTIAL CONFIDENTIAL 14 Topical Sustained - Release Delivery Antibiotics: Bacterial Keratitis/Conjunctivitis ▪ A corneal blinding condition (Scarring/perforation) ▪ Most common cause in US is contact lens wear ▪ Standard of care is topical antibiotics dosed as often as hourly ▪ No marketed drug
Slide 16: Topical Sustained-Release Delivery Antibiotics: Bacterial Keratitis/Conjunctivitis
CONFIDENTIAL CONFIDENTIAL 15 Topical Sustained - Release Delivery Antibiotics: Bacterial Keratitis/Conjunctivitis ▪ Safety and tolerability study in NZW rabbits ▪ Engineered using a Finite computational model ▪ Films molded 3 mm x 10.5 mm x 100 um when hydrated ▪ Assessing seven days of retention Co
Eyegate Pharmaceuticals — Merger or Acquisition (March 2016) on 6ix